Document:

Exhibit 10.1

 

DATED:      20th
JUNE 2022

 

 

 

 

 

 

 

TERMS OF APPOINTMENT

 

AS

 

DIRECTOR

 

(By way of Deed)

 

 

 

Between:

 

 

 

(1) MIDATECH PHARMA PLC

 

and

 

 

 

(2) STEPHEN BARRY PARKER

 

    	 	 	 

    	 

    

 

This Agreement is dated the 20th day of JUNE 2022

 

BETWEEN: 

 

		(1)	MIDATECH PHARMA PLC a company registered in England under number 09216368 whose address is at 1
Caspian Point, Caspian Way, Cardiff CF10 4DQ, UK (the “Company”); and

 

		(2)	STEPHEN BARRY PARKER (“You/you”).

 

		1.	TERMS OF APPOINTMENT

 

		1.1	You agree to your appointment as a non-executive director of the Company and as Chairman of the Board
(as defined below) and the Company agrees to your appointment on the terms and conditions of appointment set out in this agreement. You
agree to chair or serve on such other committees of the Company as the Board may determine from time to time and acknowledge that no additional
fees will be due to you for performing such additional duties.

 

		1.2	Your appointment as a non-executive director under this agreement commenced on 20 June 2022. Subject to
the terms of this agreement, your appointment shall be for an initial fixed term of twelve (12) months and will terminate on 19th
June 2023 without the need for notice (“the Initial Fixed Term”). Any continuance of your appointment after the Initial Fixed
Term will be subject to re-election by the directors of the Company on an annual basis. Your appointment as a non-executive director may
be terminated earlier:

 

		1.2.1	by either party to this agreement giving to the other party not less than three (3) months’ written
notice expiring on or after the end of the Initial Fixed Term;

 

		1.2.2	at any time in accordance with clause 9 of this agreement; or

 

		1.2.3	at any time in accordance with clause 14 of this agreement; or

 

		1.2.4	if, after the expiry of the Initial Fixed Term, you fail to be re-elected as a non-executive director
by the directors of the Company.

 

		1.3	You agree that you have no right to be appointed to or to remain a member or the chairman of any particular
committee of the Board (including, but not limited to, the Audit Committee, the Remuneration Committee and the Nomination Committee) and
that your removal from any such committee to which you are appointed shall not constitute a breach of this agreement.

 

		1.4	You shall, unless prevented by sickness or ill-health and subject always to clause 1.5, properly perform
such duties as are appropriate to your role as a non-executive director, Chairman of the Board and as the chairman or as a member of any
other committees of the Board to which you may be appointed from time to time, including, without limitation: preparing for, attending
and chairing all meetings of the Board and of the members of the Company (e.g. annual meetings and extraordinary meetings of the Company);
preparing for and attending all meetings of any committee to which you may be appointed; attending occasional meetings with the Company’s
major shareholders to obtain their views; leading discussions of the Board in relation to corporate strategy; ensuring that all members
of the Board receive accurate, timely and clear information concerning the operations and performance of the Company and its Group Companies;
preparing agendas for meetings of the Board and the members; assessing the performance of the Board and each individual director of the
Company; and reviewing and providing comments in relation to documents or minutes distributed to you following such meetings.

 

    	 	 	 

    	 

    

 

		1.5	You agree to make yourself available to attend to your duties for the Company for ten (10) full working
days per calendar year at such times and places as are reasonably necessary for the effective and efficient performance of your duties
provided that they do not conflict with your other commitments to third parties. For the avoidance of doubt, eight hours shall constitute
a full working day (and such hours need not be worked consecutively or on the same calendar day) and time spent travelling shall be counted
as working time. The Company shall, after consultation with you, provide you with reasonable notice of the dates of all meetings which
you shall be required to attend and shall use its reasonable endeavours to ensure that meetings of any committee to which you are appointed
take place immediately before or after Board meetings. For any year during which the agreement is effective for less than 12 months, the
number of days of service you are to provide, will be calculated pro rata to the number of months that this agreement is effective in
that calendar year.

 

		1.6	You will comply with all lawful and reasonable directions of the Board and all rules and regulations of
the Company provided, in each case, they have been notified to you, including without limitation, regulations with respect to confidentiality,
dealings in shares and notifications required to be made by a director to the Company or any relevant regulatory body, whether under the
company laws of England, the Companies Act, the Articles, applicable United States securities laws, the rules and regulations of the United
States Securities and Exchange Commission, or otherwise.

 

		1.7	You shall act in good faith and in the best interests of the Company and exercise all reasonable skill
and care in the performance of your duties.

 

		1.8	You confirm that you are aware of your fiduciary duties as a director and your continuing duty to avoid
a conflict between your personal and outside interests and the interests of the Company. The Company acknowledges that you have disclosed
certain existing interests to it, as referenced in clause 9.1 of this agreement and that, based on the information you have provided to
the Company, there appears to be no conflict of interests.

 

		1.9	You consent to the Company holding and processing personal data, including sensitive personal data relating
to you ("processing", personal data" and "sensitive personal data" are as defined in the Data Protection Act
1998) to the extent reasonably necessary for legal, personnel, administrative, financial, regulatory, payroll, management and other purposes
relating to or ancillary to your appointment. You agree that the Company may disclose such information to other companies within the Group
and to third parties in the event that such disclosure is in the Company's view required for the proper conduct of the Company's or the
Group's business. This applies to information held, used or disclosed in any medium and whether the use or processing of data is within
or outside the European Union

 

    	 	2	 

    	 

    

 

		2.	REMUNERATION

 

		2.1	In consideration of you performing your duties for the Company, the Company shall pay you:

 

		2.1.1	non-executive director’s fees at
the rate of £82,000 per annum, plus

 

		2.1.2	for every day in excess of 16 days worked, a per diem rate of £1,750.

 

Such non-executive
director's fees shall be paid by equal monthly instalments and shall be subject to deductions for income tax, national insurance contributions
and other deductions required by law. The rate of such non-executive director's fees shall be reviewed annually by the Remuneration Committee
in its discretion. The Remuneration Committee shall be under no obligation to increase the rate of fees paid to you as a result of any
such review but such fees may not be reduced.

 

		2.2	You will not, unless you are notified by the Company in writing at any time, be entitled to participate
in the Company’s pension scheme or employee benefits schemes other than stated under clause 3. below

 

		3.	SHARE
OPTIONS

 

		3.1	Subject to the conditions contained in this clause 3, the Company will, as soon as practicable following
execution of this Agreement, grant you options (“Options”) to acquire a number of ordinary shares par value £0.001 in
the capital of the Company (“Shares”) with an aggregate exercise price of £42,000.

 

		3.2.	The Options shall be granted on the basis that:

 

		3.2.1.	The exercise price of each Option will be based upon the mid-market closing price on the business day
before the date of grant;

 

		3.2.2	The Option may be exercised 25% on the anniversary of grant and thereafter in 12 equal tranches at the
end of the following 12 quarters;

 

		3.2.3	In the event of your death prior to exercise, the Options may be exercised by your validly appointed personal
representatives during the period of six months following the date of your death (or such longer period not exceeding 12 months determined
by the Board prior to the expiry of that six-month period).

 

		3.3.	The Options may not be transferred (other than to your personal representatives on death) and your interest
in them may not be assigned or charged.

 

		4.	FREEDOM TO TAKE UP DUTIES WITH THE COMPANY

 

You warrant that you will not, by entering into
or performing any of your duties for the Company, be in breach of any other agreement, contract or obligation binding on you.

 

    	 	3	 

    	 

    

 

		5.	FACILITIES

 

The Company shall provide you with such secretarial
and other facilities as shall be reasonably necessary and agreed between you and the Company in connection with the performance of your
duties under this agreement.

 

		6.	DIRECTORS' AND OFFICERS’ LIABILITY INSURANCE

 

The Company will take out reasonable directors'
and officers' liability insurance, which will apply to you for the duration of your appointment, subject to the terms, conditions and
limitations of such insurance cover. A copy of the policy can be obtained from the Company Secretary.

 

		7.	EXPENSES

 

The Company will reimburse you for any reasonable
travelling and other expenses you incur in performing your duties for the Company, subject to you providing the Company with receipts,
vouchers or other written evidence evidencing such expenditure (in particular, but without limitation, costs incurred on air travel, in
accordance with the company’s travel policy, will be fully reimbursed provided that the Company has pre-approved the flights. Costs
incurred on Business Class air travel for flights longer than six (6) hours will be fully reimbursed provided that the CEO of the Company
(from time to time) has pre-approved the flights.) Any air miles or other loyalty points or benefits which you may obtain as a result
of business travel shall be for your personal use.

 

		8.	PROFESSIONAL ADVICE

 

Occasions may arise when you consider that you
need professional advice in connection with the performance of your duties as a non-executive director of the Company and you will be
entitled to consult the Company's professional advisers at the Company’s expense to the extent that is reasonably necessary in all
the circumstances and that the costs incurred are reasonable and not exceeding £7,500 plus VAT. For expenses exceeding £7,500
plus VAT the agreement from the other non-executive directors or other authorised individuals of the Company is to be received prior to
you committing the expenditure.

 

		9.	OUTSIDE INTERESTS

 

		9.1	The Company acknowledges that you are the Chairman of Sareum Holdings plc and Drishti Discoveries Ltd,
a non-executive director of MGC Pharmaceuticals Ltd and an executive director of sp2 Consulting Ltd. In addition, you have
non-fiduciary roles as a Vice Chairman of Canaccord Genuity Limited and a Senior Adviser to Opus Corporate Finance LLP.

 

		9.2	You agree that you will notify the Board in writing of your intention to accept any other employment (not
listed in 9.1. above), engagement, appointment, interest or involvement in any (as the context permits) person, firm, company, corporation,
business or organisation which competes or conflicts with your appointment (an “Other Interest”). In the event that:

 

    	 	4	 

    	 

    

 

		9.2.1	the Board reasonably determines that your acceptance of any such Other Interest would result in a serious
conflict of interests; the Board will notify you in writing of this determination within 28 calendar days of receipt of your notification
to the Board regarding the Other Interest. Within 7 calendar days of receipt by you of any such notice from the Company, you will confirm
to the Board in writing whether you intend to accept the applicable Other Interest.

 

		9.2.2	you reasonably determine that your acceptance of any such Other Interest would result in a serious conflict
of interests; you will notify the Board of your view at the same time as you notify the Board of your intention to accept the Other Interest.

 

You agree that you will, if you decide
to accept the applicable Other Interest, submit to the Board (at the same time as you submit the written confirmation regarding your intentions)
your written notice of resignation as the Chairman and as a director of the Company, such resignation to take effect after a period of
3 months. It is agreed that neither the Company nor you shall not have any right to damages or compensation in relation to your resignation
in these circumstances and that all unvested Options will not vest after the date you cease to be an officer of the Company, except where
an Independent Valuation is carried out after the date you cease to be an officer of the Company but in respect of a period during which
you were appointed. You hereby irrevocably appoint any other director of the Company from time to time to be your attorney to execute
any documents and do anything in your name to effect your resignation as the Chairman and as a director of the Company should you fail
to submit your resignation to the Company in accordance with the terms stated in this clause. You agree that a written notification signed
by a director of the Company that any instrument, document or act falls within the authority conferred by this clause will be conclusive
evidence that it does so; or Notwithstanding any term of this agreement, you may hold (directly or through nominees including your spouse,
partner or minor children) by way of bona fide personal investment any units of any authorised unit trust and up to three (3%) percent
of the issued shares, debentures or other securities of any company whose shares are listed on a recognised investment exchange or on
the alternative investment market.

 

		9.3	During your appointment you shall and will procure that your spouse and minor children comply with:

 

(a)       all
applicable rules of law;

 

		(b)	any recognised investment exchange regulations (including the Model Code for Securities Transactions by
Directors of Listed Companies issued by the London Stock Exchange plc and any revisions, or amendments of the same or any equivalent regulations
issued by any other applicable investment exchange) and

 

		(c)	any policy, code or regulations of the Company or any Group Company notified to you,

 

relating (in the case of (a) to (c)
inclusive) to dealings in shares, debentures or other securities of the Company and any Group Company or relating to any unpublished price
sensitive information affecting the securities of the Company, any Group Company or any other company.

 

    	 	5	 

    	 

    

 

		10.	CONFIDENTIAL INFORMATION

 

		10.1	During the course of your appointment as a non-executive director of the Company you will have access
to and become aware of information which is confidential to the Company and the Group Companies. You undertake that you will not, save
in the proper performance of your duties for the Company, use (whether for your own benefit or for the benefit of any other person, firm,
company or organisation) or disclose to any person, firm, company or organisation (other than your professional advisers) any of the trade
secrets or other confidential information of or relating to: (a) the Company; (b) any Group Company; (c) any customer, client or Prospective
Customer (as defined below) of the Company or any Group Company; (d) any person, firm, company or organisation with whom or which the
Company is involved in any kind of business venture or partnership; or (e) the business of the Company or any Group Company, which (in
the case of each of (a) to (e) inclusive) you received or obtained during your appointment as a non-executive director of the Company.
You will likewise use your best endeavours to prevent the unauthorised publication or disclosure of any such trade secrets or confidential
information.

 

		10.2	This restriction shall continue to apply after the termination of your appointment for a period of five
years, but shall cease to apply to information ordered to be disclosed by a Court or Tribunal of competent jurisdiction or to information
which becomes available to the public generally (other than by reason of your breaching this clause).

 

		10.3	For the purposes of this agreement confidential information shall include, but shall not be limited to:

 

		(a)	corporate
and marketing strategy and plans and business development plans;

 

		(b)	budgets, management accounts, bank account details and other confidential financial data;

 

		(c)	business, sales and marketing methods, confidential techniques, know how and processes used for the production
or development of products and services; services;

 

		(d)	details and specifications of products and services being sold, provided, distributed or developed, including:
research and development reports, genetic data, databases, chemical formulae, information relating to pre-clinical or clinical trials,
medical records, proprietary vaccines, pharmaceutical compounds and nucleic acid constructs, proprietary bioinformatics, confidential
methods and processes, inventions or creations, product specifications, and details of intellectual property solutions or rights relating
to products or services;

 

		(e)	details of computer technology; computer programs; software applications and systems; information relating
to proprietary hardware or software (including updates); source and object code to proprietary software; confidential algorithms developed
or used for such proprietary software;

 

		(f)	details of the salaries, bonuses,
commissions and other employment terms applicable to employees;

 

    	 	6	 

    	 

    

 

		(g)	The names, addresses and contact details of any customers or Prospective Customers, customer lists in
whatever medium this information is stored and the requirements of those customers or the potential requirements of Prospective Customers
for any products or services. Without prejudice to the foregoing, personal information provided by visitors to and users of any of its
web sites;

 

		(h)	the terms of business with advertisers, customers and suppliers, including any pricing policy adopted
and the terms of any partnership, joint venture or other form of commercial co-operation or agreement with any third party;

 

		(i)	software and technical information necessary for the development, maintenance or operation of any websites
and the source and object code of each website;

 

		(j)	existing,
pending or threatened litigation; and

 

		(k)	Any other information which is the subject of an obligation of confidence owed to a third party, in particular
the content of discussions or communications with any Prospective Customers or prospective business partners.

 

		11.	COPYRIGHT, DESIGN RIGHTS AND OTHER RIGHTS

 

		11.1	You will promptly disclose to the Company all works in which copyrights, design rights or database rights
(or similar forms of intellectual property protection) may exist which you make or originate either by yourself or jointly with other
people during your appointment as the non-executive Chairman of the Company.

 

		11.2	Any copyright work, design or database created by you in the normal course of your appointment or in the
course of carrying out duties specifically assigned to you by the Board shall be the property of the Company whether or not the work was
made at the direction of the Company or was intended for the Company and the copyright in it and the rights in any design or database
shall belong absolutely to the Company throughout all jurisdictions and in all parts of the world, together with all rights of registration,
extensions and renewal (where relevant). direction of the Company or was intended for the Company and the copyright in it and the rights
in any design or database shall belong absolutely to the Company throughout all jurisdictions and in all parts of the world, together
with all rights of registration, extensions and renewal (where relevant).

 

		11.3	To the extent that such copyrights, design rights and database rights (and similar forms of intellectual
property protection) are not otherwise vested in the Company, you hereby assign the same to the Company, together with all past and future
rights of action relating thereto. In relation to any copyright work, design or database that may be created by you in the future, whether
in the normal course of your appointment or in the course of carrying out duties specifically assigned to you by the Board, you hereby
assign the copyright, design rights and database rights (and similar forms of intellectual property protection) in the same to the Company
with the intention that such copyright, design rights and database rights (and similar forms of intellectual property protection) should
forthwith upon completion of the relevant works vest in the Company.

 

    	 	7	 

    	 

    

 

		11.4	You recognise and accept that the Company may edit copy, add to, take from, adapt, alter and translate
the product of your services in exercising the rights assigned under clause 11.3.

 

		11.5	To the full extent permitted by law, you irrevocably and unconditionally waive any provision of law known
as “moral rights” including any moral rights you may otherwise have under sections 77 to 85 inclusive of the Copyright Designs
and Patents Act 1988 in relation to the rights referred to at clause 11.2. You give this waiver in favour of the Company and each Group
Company, and all successors in title to and licensees of the copyright design right and database right in such works (whether existing
or future).

 

		11.6	You agree that you will at the Company's request and expense while you remain a director of the Company
and for a period of five (5) years after ceasing to be a director of the Company, execute such further documents or deeds and do all things
necessary or reasonably required to confirm and substantiate the rights of the Company under this clause 11.

 

		11.7	You agree that you will not at any time make use of, disclose or exploit the Company's property, trade
marks, service marks, documents, materials or information in which the Company or any Group Company owns (wholly or partially) the copyright,
design right, database right or semi-conductor topography right (or similar forms of intellectual property protection) for any purpose
which has not been authorised by the Company in advance.

 

		11.8	Notwithstanding anything in clauses 10, 11, 12 or 13 of this agreement, you shall own and retain ownership
of and may freely use, disclose and exploit any copyright relating to your written business presentations provided that you have first
deleted any confidential information relating to the Company or any Group Company from such presentations and that such use, disclosure
or exploitation does not infringe or use any of the Company’s trade secrets, trademarks, copyrights or other intellectual property
rights.

 

		12.	INVENTIONS

 

		12.1	It shall be part of your normal duties at all times to consider at a strategic level in what manner and
by what new methods or devices, products, services, processes, equipment or systems of the Company and each Group Company might be improved
and to further the intellectual property interests of the Company. You and the Company agree that, because of the nature of your duties
and the particular responsibilities arising from your duties, you have a special obligation to further the interests of the Company.

 

		12.2	You hereby acknowledge and agree that the sole ownership of any invention, discovery, design, improvement
or other matter or work whatsoever made or discovered by you from time to time in the course of your appointment and all proprietary rights
therein discovered or made by you (whether alone or jointly with others) at any time during your appointment (the “Company Inventions”)
shall (subject to any contrary provisions of the Patents Act 1977 and the Copyright Designs and Patents Act 1988 and to any rights of
a joint inventor thereof) belong free of charge and exclusively to the Company or as it may direct.

 

    	 	8	 

    	 

    

 

		12.3	You shall promptly give to the Board full details of all inventions, discoveries, designs, improvements
or other matter or works whatsoever made or discovered by you from time to time during the continuance of your appointment with the Company.

 

		12.4	All worldwide copyright, design rights and database rights in all Company Inventions shall be and remain
the property of the Company and the provisions of clause 11 above shall apply in relation to the same.

 

		12.5	You agree that you shall, while you remain a director of the Company and for a period of five (5) years
after ceasing to be a director of the Company, at the Company's expense, do all such acts and things and execute such documents (including
without limitation making application for letters patent) as the Board may reasonably request in order to vest effectually all Company
Inventions, to the extent that the same is the property of the Company or any other Group Company, and any protection as to ownership
or use (in any part of the world) of the same, in the Company or any Group Company, or as the Company may direct, and you hereby irrevocably
appoint the Company for these purposes to be your attorney in your name and on your behalf to execute and do such acts and things and
execute any such documents as set out above.

 

		12.6	You agree that you will not knowingly do or omit to do anything which will or may have the result of imperilling
any such protection aforesaid or any application for such protection.

 

		12.7	You agree that you will not at any time make use of, disclose or exploit any Company Invention belonging
wholly or partially to the Company or any Group Company for any purpose which has not been authorised by the Company.

 

		12.8	Each of the provisions in this clause 12 is distinct and severable from the others and if at any time
one or more of such provisions is or becomes invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining
provisions of the clause will not in any way be affected or impaired.

 

		13.	COMPANY PROPERTY

 

		13.1	You may not, save in the proper performance of your duties as a director or with the Company's prior written
permission, remove any property belonging to the Company or any Group Company or relating to the affairs of the Company or any Group Company
from the Company's or any Group Company's premises, or make any copies of documents or records relating to the Company's or any Group
Company's affairs.

 

		13.2	Upon the Company's request at any time and in any event on the termination of your appointment as a non-executive
director of the Company, you agree to deliver up to the Company or its authorised representative within two working days or such request
from the Company or the termination of your appointment, any and all plans, keys, mobile telephone, security passes, credit cards, customer
lists, price lists, equipment, documents, records, papers, computer disks tapes or other computer hardware or software or memory medium
or devices (together with all copies of the same), and all property of whatever nature in your possession or under your control which
belongs to the Company or any Group Company or relates to its or their business affairs. You will, at the Company's request and without
delay, furnish the Company with a written statement confirming that you have complied with this obligation.

 

    	 	9	 

    	 

    

 

		14.	TERMINATION

 

		14.1	In the event that the Company terminates your offices of directorship at any time in accordance with the
provisions of the Articles (as amended by the Company from time to time) and/or any applicable laws (including where applicable the Laws
of the UK and the Companies Act), you agree that you shall have no right to any damages or compensation on or after the date you cease
to be a director of the Company if you:

 

		(a)	are guilty of any gross misconduct, gross negligence or dishonesty or act in a manner which is materially
adverse to the interests of the Company;

 

		(b)	commit any serious or repeated breach or non-observance of your obligations to the Company (which include
an obligation not to breach your statutory, fiduciary or common-law duties);

 

		(c)	become bankrupt, have an interim order made against you under the Insolvency Act 1986 or make any composition
or enter into any deed of arrangement with your creditors or the equivalent of any of these under any other jurisdiction;

 

		(d)	become of unsound mind, become a patient under any mental health legislation or be unable due to any accident,
illness or injury to undertake your duties for the Company in accordance with the terms of this agreement for a period of more than 6
consecutive months;

 

		(e)	are convicted of a criminal offence (other than a motoring offence for which a non-custodial sentence
is imposed on you);

 

		(f)	become disqualified by law or any court of competent jurisdiction from acting as a director of a company;
or

 

		(g)	have failed to submit your resignation as the chairman and as a director of the Company when required
to do so under the terms agreed in clause 9.2 of this agreement.

 

		14.2	In the event that the Company terminates your office as a director of the Company at any time with immediate
effect (other than in accordance with clause 14.1 of this Agreement), the Company shall pay you all director’s fees which would
have been due to you for the following twelve (12) months within 14 days of the date of such termination. The parties to this agreement
agree that this is a reasonable pre-estimate of your loss.

 

		14.3	You may resign from your office as a director and as Chairman of the Company with immediate effect if
the Company:

 

		(a)	is guilty of any gross negligence which affects you or any dishonesty towards or concerning you; or

 

    	 	10	 

    	 

    

 

		(b)	Becomes insolvent, makes any composition or enters into any deed of arrangement with its creditors or
the equivalent of any of these under any other jurisdiction.

 

		14.4	In the event that you resign from your appointments at any time for any reason which is stated in clauses
14.3(a)–(b) inclusive, the Company shall pay you all director’s fees which would have been due to you for the following twelve
(12) months within 14 days of the date of such termination. The parties to this agreement agree that this is a reasonable pre-estimate
of your loss.

 

		14.5	In the event that you are unable due to any accident, illness or injury to undertake your duties for the
Company in accordance with the terms of this agreement for a period of more than 6 consecutive months you may thereafter resign from your
office as a director of the Company at any time and without the Company having any right to damages or compensation.

 

		14.6	In the event that you wish to resign your office as a director of the Company for a reason other than
those stated in clause 9.2, clause 14.3(a)-(b) inclusive or clause 14.5 you agree to give the Company not less than twelve (12) months’
written notice of resignation.

 

		14.7	Notwithstanding any other term of this agreement, you agree that the Company may terminate your appointment
as a director under this agreement at any time after the Initial Fixed Term by giving to you not less than three (3) months’ written
notice of termination expiring on or after the end of the Initial Fixed Term. In the event that notice is given to you by the Company,
you agree that, prior to the expiry of the notice period, you will submit to the Board your written resignation as the Chairman and as
a director of the Company, such resignation to take effect on the expiry of the said notice period. You hereby irrevocably appoint any
other director of the Company from time to time to be your attorney to execute any documents and do anything in your name to effect your
resignation as the Chairman and as a director of the Company should you fail to resign on or before the date of expiry of such period
of notice of termination given to you by the Company. You agree that a written notification signed by a director of the Company that any
instrument, document or act falls within the authority conferred by this clause will be conclusive evidence that it does so.

 

		14.8	Upon the termination of your appointment as a non-executive director of the Company for whatever reason
or at the request of the Board, you shall resign promptly (with such resignation taking immediate effect) from all other directorships
held by you in any Group Company. You hereby irrevocably appoint the Company to be your attorney to execute any documents and does anything
in your name to effect your resignation as a director of any Group Company should you fail to resign promptly following a request from
the Company to do so in accordance with this clause. A written notification signed by a director of the Company that any instrument, document
or act falls within the authority conferred by this clause will be conclusive evidence that it does so.

 

		15.	DEFINITIONS

 

		15.1	Any reference in this agreement to:

 

    	 	11	 

    	 

    

 

		15.2	any Act or delegated legislation includes any statutory modification or re-enactment of it or the provision
referred to;

 

		15.3	“the Articles” means the Articles of Association of the Company as amended from time to time;

 

		15.4	“the Board” shall mean the Board of Directors of the Company from time to time or any person
or any committee of the Board duly appointed by it;

 

		15.5	“The Companies Act” means the Companies Act 2006;

 

		15.6	“Group Company” means a company which from time to time is a subsidiary or a holding company
of the Company or a subsidiary of such holding company (where the terms “subsidiary” and “holding company” have
the meanings attributed to them in section 1159 of the Companies Act);

 

		15.7	“Prospective Customer” means any person with whom the Company or any Group Company is in negotiations
in relation to the sale or supply of goods and/or services by the Company or any Group Company to such person or to whom the Company or
any Group Company has submitted a tender relating to such sale or supply arrangement; and

 

		15.8	“Effective Date” means the date on which the appointment as non executive director and Chairman
becomes effective.

 

		16.	JURISDICTION/LANGUAGE OF THE CONTRACT

 

		16.1	This agreement is governed by and construed in accordance with the laws of England and Wales and the parties
submit to the non-exclusive jurisdiction of the English courts.

 

    	 	12	 

    	 

    

 

IN WITNESS WHEREOF this agreement has been
executed and delivered as a deed on the date set out above.

 

 

 

EXECUTED and DELIVERED as a DEED

by MIDATECH PHARMA PLC

 

 

	Acting by:	 /s/ Stephen Stamp........................................ 
	 	Director

 

 

	 	.../s/ Rolf Stahel..................................... 
	 	Director

 

 

 

 

EXECUTED and DELIVERED as a DEED 

 

	by STEPHEN B. PARKER: 	.../s/ Stephen B. Parker.................................... 

 

in the presence of:

 

	Signature of witness 	.../s/ Doris Campbell.................................... 
	 	 
	Print name of witness 	...Doris Campbell................................. 
	 	 
	Print address of witness 	....................................... 
	 	 
	 	....................................... 
	 	 
	Print occupation of witness	....................................... 

 

 

13Exhibit 4.1

 

	 	NUMBER UNITS U-
	SEE REVERSE FOR CERTAIN DEFINITIONS	CUSIP G4233U 123
	 	 

 

HAINAN MANASLU ACQUISITION CORP.

UNITS CONSISTING OF ONE ORDINARY SHARE, ONE-HALF
OF ONE

WARRANT TO PURCHASE ONE ORDINARY SHARE, AND ONE RIGHT

TO RECEIVE ONE-TENTH OF ONE ORDINARY SHARE

 

	THIS CERTIFIES THAT	 	is the owner of	 	Units.

 

Each Unit (“Unit”)
consists of one ordinary share, par value $0.0001 per share (“Ordinary Shares”), of Hainan Manaslu Acquisition
Corp., a Cayman Islands exempted company (the “Company”), one-half of one warrant (the “Warrant”),
and one right (the “Right”). Each whole Warrant entitles the holder to purchase one Ordinary Share (subject
to adjustment) for $11.50 per share (subject to adjustment). Only whole Warrants are exercisable. Each whole Warrant will become exercisable
on the later of (i) the Company’s completion of a merger, share exchange, asset acquisition, share purchase, reorganization or other
similar business combination with one or more businesses (each a “Business Combination”), and (ii) twelve (12)
months from the effective date of the Company’s Registration Statement on Form S-1 for its initial public offering (File No. 333-261340),
and will expire, unless exercised before 5:00 p.m., New York City Time, on the date that is five (5) years after the date on which the
Company completes its initial Business Combination, or earlier upon redemption or liquidation. Each Right entitles the holder thereof
to receive one-tenth of one Ordinary Share upon the consummation of the initial Business Combination. The Ordinary Shares, Warrants and
Rights comprising the Units represented by this certificate are not transferable separately prior to [    ], 2022, unless
Ladenburg Thalmann & Co. Inc. elects to allow separate trading earlier, subject to the Company’s filing of a Current Report
on Form 8-K with the U.S. Securities and Exchange Commission containing an audited balance sheet reflecting the Company’s receipt
of the gross proceeds of its initial public offering and issuing a press release announcing when separate trading will begin. No fractional
Warrants will be issued upon separation of the Units. The terms of the Warrants and Rights are governed by a Warrant Agreement, dated
as of [    ], 2022, between the Company and Continental Stock Transfer & Trust Company (“CST”),
as Warrant Agent, and a Rights Agreement dated as of [    ], 2022, between the Company and CST, as Rights Agent, respectively,
and are subject to the terms and provisions contained therein, all of which terms and provisions the holder of this certificate consents
to by acceptance hereof. Copies of the Warrant Agreement and the Rights Agreement are on file at the office of the Warrant Agent and Rights
Agent at One State Street, New York, 30th Floor, New York 10004, and are available to any Warrant holder and Right holder on
written request and without cost.

 

This certificate is not valid unless countersigned
by the Transfer Agent and registered by the Registrar of the Company.

 

This certificate shall be governed
by and construed in accordance with the internal laws of the State of New York.

 

Witness the facsimile signature of its duly authorized
officers.

 

	 	 	 
	Chief Executive Officer	 	Secretary

 

     

     

    

 

Hainan Manaslu Acquisition Corp.

 

The Company will furnish without
charge to each unitholder who so requests, a statement of the powers, designations, preferences and relative, participating, optional
or other special rights of each class of shares or series thereof of the Company and the qualifications, limitations, or restrictions
of such preferences and/or rights.

 

The following abbreviations,
when used in the inscription on the face of this certificate, shall be construed as though 

 

	TEN COM	 	- 	as tenants in common	 	UNIF GIFT MIN ACT -	Custodian 
	TEN ENT	 	-	as tenants by the entireties	 	 	(Cust)                    (Minor)
	JT TEN	 	-	as joint tenants with right of survivorship and not as tenants in common	 	 	under Uniform Gifts to Minors
	 	 	 	 	 	 	Act	 
	 	 	 	 	 	 	 	(State)

 

Additional abbreviations may also be used though
not in the above list.

 

For value received, hereby sell, assign and transfer unto

 

	 
	PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE
	 
	 
	(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE)
	 
	 
	Units represented by the within Certificate, and does hereby irrevocably constitute and appoint
	 
	Attorney to transfer the said Units on the books of the within named Company with full power of substitution in the premises.
	 	 	 
	Dated: 	 	 

 

    2

     

    

 

	 	 	 
	 	 	Notice:   	The signature to this assignment must correspond with the name as written upon the face of the certificate in every particular, without alteration or enlargement or any change whatever.
	Signature(s) Guaranteed:	 	 
	 	 	 
	THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED OR ANY SUCCESSOR RULE).	 	 

 

In each case, as more fully described in the Company’s
final prospectus dated [ ], 2022, the holder(s) of this certificate shall be entitled to receive a pro-rata portion of certain funds held
in the trust account established in connection with its initial public offering only in the event that (i) the Company redeems the ordinary
shares sold in its initial public offering and liquidates because it does not consummate an initial Business Combination within the timeframe
set forth in the Company’s amended and restated memorandum and articles of association (the “Deadline”),
(ii) the Company redeems the ordinary shares sold in its initial public offering in connection with a shareholder vote to amend the Company’s
amended and restated memorandum and articles of association (i) to modify the substance or timing of its obligation to provide holders
of its ordinary shares the right to have their shares redeemed in connection with the Company’s initial Business Combination or
to redeem 100% of its public shares if the Company does not complete its initial Business Combination by the Deadline or (ii) with respect
to the other provisions relating to shareholders’ rights or pre-business combination activity, or (iii) if the holder(s) seek(s)
to redeem for cash his, her or its respective ordinary shares in connection with a tender offer (or proxy solicitation, solely in the
event the Company seeks shareholder approval of the proposed initial Business Combination) setting forth the details of a proposed initial
Business Combination. In no other circumstances shall the holder(s) have any right or interest of any kind in or to the trust account.

 

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]